Physician profile
Alan D Gaines
NPI 1841397981
$7,644.89
in general payments reported to CMS, 2019-2025
34 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $601 · 2021: $1,135 · 2022: $1,463 · 2023: $1,282 · 2024: $1,086 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.42 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,704.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,296.32 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,289.64 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $709.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $327.75 | 2019-2025 | |
| Pfizer INC. | $246.11 | 2019-2025 | |
| Abbvie INC. | $228.55 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $221.64 | 2021-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.89 | 2019-2024 | Spiriva Respimat |
| Aimmune Therapeutics, INC. | $151.44 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.33 | 2020-2024 | Cuvitru |
| Kaleo, INC. | $119.73 | 2019-2023 | Auvi-Q |
| Amgen INC. | $114.64 | 2022-2024 | Tezspire |
| Csl Behring | $93.37 | 2019-2024 | Hizentra, Haegarda |
| Covis Pharma Gmbh | $85.50 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $85.29 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $83.84 | 2025 | Neffy |
| Pharming Healthcare, INC. | $82.45 | 2019-2025 | Ruconest |
| Shire North American Group INC | $78.40 | 2019 | |
| Optinose US, INC. | $76.54 | 2019-2023 | |
| Incyte Corporation | $54.27 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $52.75 | 2022-2023 | Adbry |
| Genentech USA, INC. | $42.05 | 2022-2025 | Xolair |
| Blueprint Medicines Corporation | $34.75 | 2023 | Ayvakit |
| Cycle Pharmaceuticals INC | $24.66 | 2025 | Sajazir |
| Arcutis Biotherapeutics, INC. | $20.71 | 2025 | Zoryve |
| Verona Pharma, INC. | $20.18 | 2025 | Ohtuvayre |
| Biocryst Pharmaceuticals, INC. | $19.58 | 2020 | |
| Horizon Therapeutics Plc | $18.53 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.63 | 2021 | |
| Galderma Laboratories, L.P. | $15.24 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $15.16 | 2024 | Orladeyo |
| Circassia INC. | $12.82 | 2020 | |
| Eyevance Pharmaceuticals LLC | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.